From: Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials
Immunomodulating therapy | Treatment length | Number of patients free from/total number of patients | Period free from insulin (average) |
---|---|---|---|
Prednisone2 | 12 months (daily use) | 4/17 | 3 months |
Prednisone + azathioprine4 | 12 months (daily use) | 10/20 | 1 week |
Azathioprine3 | 12 months (daily use) | 0/24 | 0 |
Ciclosporin5 | 24 months (daily use) | 53/122 | 10 months |
Antibody anti-CD36 | E.V. application 6 days in a row | 0 | 0 |
Heat shock protein7 | 1 S.C. application in time 0, + 1 and + 6 months | 0 | 0 |
Anti-thymocyte globulin8 | E.V. Applications 4 days in a row | 0 | 0 |
Glutamic acid decarboxylase9 | 2 subcutaneous applications with 1-month interval | 0 | 0 |